11th February 2025 (12 Topics)
1
Feb
3
Feb
4
Feb
5
Feb
6
Feb
7
Feb
8
Feb
10
Feb
11
Feb
12
Feb
Biolumpivaxin Vaccine
Context
Bharat Biotech’s group company, Biovet, has received approval from the Central Drugs Standard Control Organisation (CDSCO) to market a vaccine against Lumpy Skin Disease (LSD) in dairy cattle and buffaloes. This vaccine, named Biolumpivaxin is the world’s first Differentiating Infected from Vaccinated Animals (DIVA) marker vaccine for LSD.
About the Vaccine (Biolumpivaxin):
- Biolumpivaxin is a live-attenuated marker vaccine developed by Biovet in collaboration with the Indian Council of Agricultural Research-National Research Centre on Equines (ICAR-NRCE).
- The vaccine uses the LSD virus/Ranchi/2019 strain and provides single-dose vaccination for cattle and buffaloes above 3 months of age.
- It is the world’s only DIVA marker vaccine, allowing the distinction between vaccinated and naturally infected animals.
- Storage and Efficacy: The vaccine is stable at a temperature range of 2-80°C and has shown high safety and efficacy.
- Production Capacity: Biovet can produce up to 500 million doses of the vaccine, which will be commercially available soon.
- Significance: This vaccine marks a crucial step toward India's self-reliance in veterinary healthcare, supporting the Atmanirbhar Bharat initiative and reducing dependency on imported vaccines.
About:Lumpy Skin Disease (LSD):
|
Courses
Study
Notes
Home
Resources
More
